Tyra Biosciences Cash Flow Statement
NASDAQ: TYRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
19.94-0.03 (-0.15%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tyra Biosciences free cash flow
In fiscal 2025, Tyra Biosciences generated -$95.1 million of operating cash flow and spent $141,000 on capital expenditures. That left free cash flow of -$95.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Tyra Biosciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M | -9.34M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 546.00K | 519.00K | 357.00K | 296.00K | 140.00K | 47.00K |
| Stock-Based Compensation | 28.01M | 22.80M | 13.53M | 10.59M | 2.89M | 439.00K |
| Change in Working Capital | 3.37M | -744.00K | 9.37M | 2.36M | 1.49M | 1.02M |
| Operating Cash Flow | -95.14M | -69.77M | -50.14M | -50.28M | -23.75M | -7.76M |
| Capital Expenditures | -141.00K | -664.00K | -770.00K | -559.00K | -661.00K | -312.00K |
| Investing Cash Flow | 72.46M | -98.40M | -144.60M | -559.00K | -645.00K | -312.00K |
| Financing Cash Flow | 8.10M | 202.14M | 1.54M | 632.00K | 311.35M | 23.43M |
| Net Change in Cash | -14.58M | 33.96M | -193.21M | -50.21M | 286.96M | 15.36M |
| Free Cash Flow | -95.28M | -70.44M | -50.91M | -50.84M | -24.41M | -8.07M |
This table shows 6 annual periods of Tyra Biosciences's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TYRA's reporting calendar. What is a cash flow statement?